Year Founded
1996
Ownership
Public
Therapeutic Areas
Psychiatry
Stage
Commercial
Modalities
Small molecule

Transcept Pharmaceuticals General Information

Merged with Paratek Pharmaceuticals in 2014. Previously developed INTERMEZZO (zolpidem tartrate) sublingual tablet for insomnia.

Contact Information

Website
Primary Industry
[ "Pharma" ]
Corporate Office
,
United States

Drug Pipeline

zolpidem tartrate
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Transcept Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Transcept Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Transcept Pharmaceuticals's complete valuation and funding history, request access »

Transcept Pharmaceuticals Investors

Not specifically listed but included a broad investor syndicate at the time of the Paratek transaction
Investor Type: Venture Capital
Holding: Minority
InterWest Partners
Investor Type: Venture Capital
Holding: Minority